Sandy Fung, MD
Family Medicine · New York, NYNPI 1982670634
Payments from drug & device makers
Across 354 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Amarin Pharma, Inc.$545
- Amgen$533
- GSK$516
- Lilly USA, LLC$444
- Gilead$406
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,587100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 134 | $2,825 |
| Amarin Pharma, Inc. | 32 | $545 |
| Amgen | 31 | $533 |
| GSK | 30 | $516 |
| Lilly USA, LLC | 23 | $444 |
| Gilead | 13 | $406 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $329 |
| AbbVie | 10 | $227 |
| Merck | 12 | $209 |
| Boehringer Ingelheim | 8 | $201 |
| Esperion Therapeutics, Inc. | 3 | $199 |
| Bayer | 4 | $190 |
| Agios Pharmaceuticals, Inc. | 1 | $156 |
| Pfizer | 6 | $134 |
| Astellas Pharma US Inc | 6 | $124 |
| Medtronic | 1 | $111 |
| Phathom Pharmaceuticals, Inc. | 3 | $110 |
| Novo Nordisk | 4 | $87 |
| Kowa Pharmaceuticals America, Inc. | 4 | $86 |
| Seqirus USA Inc | 5 | $81 |
| Johnson & Johnson | 2 | $47 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,595 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 1,365 | $839,228 |
| JardianceEmpagliflozin | 289 | $324,576 |
| FarxigaDapagliflozin Propanediol | 163 | $161,556 |
| JanuviaSitagliptin Phosphate | 146 | $150,275 |
| Diclofenac Epolamine | 249 | $93,944 |
| EliquisApixaban | 80 | $63,853 |
| JanumetSitagliptin Phos/Metformin Hcl | 66 | $59,259 |
| Xigduo XrDapaglifloz Propaned/Metformin | 58 | $56,278 |
| MyrbetriqMirabegron | 104 | $54,365 |
| ProliaDenosumab | 26 | $45,020 |
| RybelsusSemaglutide | 24 | $40,294 |
| LivaloPitavastatin Calcium | 46 | $36,272 |
| VemlidyTenofovir Alafenamide | 18 | $34,447 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $33,558 |
| Diclofenac Sodium | 404 | $31,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $201 | $350,570329 claims |
| MerckJanuvia, Janumet | $209 | $209,534212 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,825 | $204,651247 claims |
| PfizerEliquis | $134 | $63,85380 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $54,365104 claims |
| AmgenProlia | $533 | $45,02026 claims |
| AbbVieLinzess, Namzaric, Synthroid | $227 | $42,041147 claims |
| Novo NordiskRybelsus | $87 | $40,29424 claims |
| GSKTrelegy Ellipta, Shingrix | $516 | $36,842102 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $86 | $36,27246 claims |
| GileadVemlidy | $406 | $34,44718 claims |
| Johnson & JohnsonInvokana | $47 | $6,14111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in New York
- Matthew PabisNew York$222K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Jason KindtNew York$122K
- Punyadech PhotangthamNew York$107K
- Mahyar EidgahNew York$76K
- Anthony LyonNew York$65K
- Daniel BowersNew York$44K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.